Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

This research study is for people in the UK who have mantle cell lymphoma (MCL), a type of blood cancer. We are looking into a new medicine called pirtobrutinib. This drug works in a similar way to other treatments already approved by health bodies. The main aim is to see how pirtobrutinib compares to these existing medicines (like ibrutinib, acalabrutinib, or zanubrutinib) in patients who have already had at least one treatment for their MCL but haven't used this type of drug before. Participants could be in the study for up to two years, or even longer if their cancer doesn't get worse, allowing us to understand the long-term effects of the treatment.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Loxo Oncology, Inc.
Einschreibeziel
500
Starten
08 Apr 2021
Geschätzte Fertigstellung
01 Jun 2030

Worum geht es in dieser Studie?

This study is an important step in finding better ways to treat mantle cell lymphoma (MCL), a type of blood cancer. Many patients with MCL benefit from a group of medicines called BTK inhibitors. These drugs work by blocking a specific protein in cancer cells, which helps to stop the cancer from growing. There are already some approved BTK inhibitors available, and they have helped many people.

This study introduces a new drug called pirtobrutinib (also known as LOXO-305), which is also a BTK inhibitor. We want to see how pirtobrutinib compares to the existing, approved BTK inhibitors. We're particularly interested in patients who have already tried at least one other treatment for their MCL but haven't previously taken a BTK inhibitor. By comparing the new drug with established ones, we hope to learn if pirtobrutinib is a safe and effective new option for these patients.

This is a 'Phase 3' study, which means it's one of the final stages of testing a new medicine before it can potentially be approved for wider use. It's a randomised study, meaning participants will be randomly chosen to receive either pirtobrutinib or one of the existing treatments. This helps us to get reliable results about how well each treatment works. Your participation could help us improve treatment options for people with MCL in the future.

Wichtige Erkenntnisse

  • Compares a new drug (pirtobrutinib) to existing approved treatments for MCL.
  • For adults with MCL who have had at least one prior treatment.
  • A 'Phase 3' study, which is a key step towards potential approval.
  • Close medical monitoring and support throughout the study.
  • Your participation could help improve future treatments for MCL.

Wer könnte berechtigt sein?

To join this study, you must have a confirmed diagnosis of mantle cell lymphoma (MCL) and have already received at least one course of treatment for it. Your lymphomamust be measurable, meaning doctors can track its size. You also need to be generally well enough to take part, as assessed by your doctor, and have certain blood test results within a healthy range, including your blood cell counts, liver function, and kidney function.

There are also some reasons why you might not be able to join. For example, if you've already had a BTK inhibitor drug, which is the type of drug being studied, then this trial wouldn't be suitable for you. If you've recently had a stroke or certain types of stem cell or CAR-T cell transplant, or have some serious heart conditions, these would also prevent you from participating. Additionally, certain infections, significant bleeding problems, or issues with absorbing medicines might mean you can't join. Your doctor will carefully review all your health information to see if this study is right for you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Do I have a confirmed diagnosis of Mantle Cell Lymphoma (MCL)?
  2. Have I already received at least one prior treatment for my MCL?
  3. Have I *never* taken a BTK inhibitor drug (like ibrutinib, acalabrutinib, or zanubrutinib) before?
  4. Am I generally well enough for a clinical trial, based on my doctor's assessment?
  5. Do I have healthy enough blood counts and organ function (liver, kidney)?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, it could last for about two years, and possibly longer if the treatment is helping you. You will be randomly assigned to receive either the new drug, pirtobrutinib, or one of the approved BTK inhibitors (ibrutinib, acalabrutinib, or zanubrutinib). You will take the study medication as prescribed by the research team. Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and scans to see how you're responding to the treatment and to monitor your health. These visits will help the medical team track your progress, manage any side effects, and ensure your safety. You'll be closely supported by the study team throughout your involvement.

Potenzielle Risiken und Vorteile

Taking part in this study may offer potential benefits, such as accessing a new treatment (pirtobrutinib) that isn't yet widely available, or receiving one of the standard approved treatments under close medical supervision. However, like all medications, both the new drug and the approved ones carry potential risks and side effects, some of which could be serious. All potential side effects will be fully explained to you by the study team. You have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (189)

  • Alaska Oncology and Hematology, LLC
    Verifizierte Postleitzahl
    Anchorage, Vereinigte Staaten
  • Arizona Oncology Associates, P.C. - HOPE
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • UCLA Medizinisches Zentrum
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • USO-Rocky Mountain Cancer Center
    Verifizierte Postleitzahl
    Denver, Vereinigte Staaten
  • Mayo Clinic in Florida
    Verifizierte Postleitzahl
    Jacksonville, Vereinigte Staaten
  • Oncology-Hematology Associates of West Broward
    Verifizierte Postleitzahl
    Tamarac, United States
  • Florida Cancer Specialists East
    Verifizierte Postleitzahl
    West Palm Beach, Vereinigte Staaten
  • University of Kentucky Markey Cancer Center
    Verifizierte Postleitzahl
    Lexington, Vereinigte Staaten
  • Mercy Health-Paducah Medical Oncology and Hematology
    Verifizierte Postleitzahl
    Paducah, United States
  • Tulane Cancer Center Office of Clinical Research
    Verifizierte Postleitzahl
    New Orleans, Vereinigte Staaten
  • Greenebaum Comprehensive Cancer Center
    Verifizierte Postleitzahl
    Baltimore, Vereinigte Staaten
  • DFCI Lymphoma
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten

Häufige Fragen

What is Mantle Cell Lymphoma (MCL)?

MCL is a rare type of cancer that affects white blood cells called lymphocytes, which are part of your immune system. It can affect your lymph nodes, spleen, blood, and bone marrow.

What is pirtobrutinib (LOXO-305)?

Pirtobrutinib is an experimental drug designed to treat certain blood cancers, including MCL. It's a 'BTK inhibitor,' meaning it blocks a specific protein in cancer cells to stop them from growing.

What does 'Phase 3' mean for a study?

Phase 3 is a late stage of clinical research where a new drug is compared to existing treatments or a placebo in a large group of people. This helps confirm its effectiveness and monitor side effects before it can be approved.

Werde ich wissen, welche Behandlung ich bekomme?

Yes, this is an 'open-label' study. This means both you and your doctor will know whether you are receiving pirtobrutinib or one of the other approved BTK inhibitor drugs.

Wie lange werde ich an der Studie teilnehmen?

Participation can last up to two years, and potentially longer if the treatment is working well for you and your cancer doesn't get worse.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.